the republic logo

First-of-a-kind Novartis heart failure drug saves lives, cuts hospitalizations in big study

bug
Share/Save/Bookmark

A new study reports one of the biggest potential advances against heart failure in more than a decade. Doctors say that a first-of-a-kind, experimental drug cut the chances of death or hospitalization by about 20 percent.

The drug, made by Switzerland-based Novartis, does not have a name yet and is just called LCZ696. If it wins federal approval, doctors say it could quickly change care for more than half of the 6 million Americans and 24 million people worldwide with heart failure.

The study involved nearly 8,500 people and was stopped early once independent monitors saw the Novartis drug was better.

Results were discussed Saturday at a cardiology conference in Barcelona and published by the New England Journal of Medicine.

Get all your favorite Health & Medicine news by following our Health & Medicine feed on Twitter! Click Here!

 

Think your friends should see this? Share it with them!

Story copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Feedback, Corrections and Other Requests: AP welcomes feedback and comments from readers. Send an email to info@ap.org and it will be forwarded to the appropriate editor or reporter.


We also have more stories about:
(click the phrases to see a list)

Category:

Follow The Republic:

All content copyright ©2014 The Republic, a division of Home News Enterprises unless otherwise noted.
All rights reserved. Privacy policy.